v3.26.1
Schedule of Segment Financial Performance (Details) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Segment Reporting [Line Items]      
Total assets $ 584,654,613   $ 519,146,435
Loss from operations (36,868,311) $ (2,546,669)  
Unrealized loss on digital assets holdings (15,013,304)  
Consolidated total loss before income taxes (51,563,437) (2,541,704)  
Digital Asset Treasury [Member]      
Segment Reporting [Line Items]      
Total assets 582,999,512   513,964,900
Loss from operations (35,221,181)  
Other income (expense) () [1] 318,178  
Unrealized loss on digital assets holdings (15,013,304)  
Consolidated total loss before income taxes (49,916,307)  
Clinical Stage Bio Technology [Member]      
Segment Reporting [Line Items]      
Total assets 1,655,101   $ 5,181,535
Loss from operations (1,647,130) (2,546,669)  
Other income (expense) () [1] 4,965  
Consolidated total loss before income taxes $ (1,647,130) $ (2,541,704)  
[1] Other income (expense) consists of interest income and interest expense.